ReviewApplied biochemistry and biotechnology2026
Investigational Anticancer Potential and Targeted Delivery Aspects of Benzyl Isothiocyanate (BITC) in Breast Cancer Treatment.
Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dietary isothiocyanates as redox-active bioactives: A comprehensive review of chemistry.Food chemistry. Molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains the most commonly diagnosed cancer among women worldwide and a leading cause of cancer-related mortality. Despite advances in early detection and treatment modalities, challenges such as recurrence, metastasis, and therapy resistance persist, necessitating the development of novel therapeutic strategies. Benzyl isothiocyanate (BITC), a naturally occurring isothiocyanate derived from cruciferous vegetables, has emerged as a promising anticancer agent due to its potent chemopreventive and therapeutic properties. This review comprehensively explores the investigational potential of BITC in the management of breast cancer, emphasizing both its molecular mechanisms and its targeted delivery through nanotechnological approaches. The chemistry and pharmacology of BITC are discussed, highlighting its ability to modulate key signaling pathways, induce apoptosis, inhibit metastasis, and arrest the cell cycle in breast cancer cells. Special attention is given to its pharmacokinetic profile, including bioavailability and metabolic stability, which are crucial for clinical translation. Furthermore, the review examines preclinical findings that demonstrate BITC's suppressive effects on tumor growth and its synergistic interactions with conventional therapies. Innovative strategies for BITC delivery, such as nanoparticle-based systems, are also evaluated for their potential to enhance therapeutic efficacy and reduce systemic toxicity. The safety profile and toxicity considerations of BITC are critically assessed based on current preclinical evidence. By synthesizing findings from a broad range of preclinical studies, this review underscores the multifaceted anticancer potential of BITC and its promise as a complementary or alternative approach in breast cancer treatment. Continued research into its mechanistic actions, delivery optimization, and translational applications is essential to harness BITC's full potential in improving patient outcomes.
Indexed as
Identifiers
41182545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.